Immunotherapy

Wednesday, October 18, 2017 - 3:45pm
Roswell Park is one of very few institutions in the United States equipped to offer clinical trials of a full range of immunotherapies. How do these treatments work, and what new immunotherapy clinical trials are underway or close to being launched?
Tuesday, October 17, 2017 - 12:48pm
Clinical trials are a key reason why childhood cancer treatments and survival rates have improved significantly in recent years.
Monday, October 16, 2017 - 1:59pm
Dr. Gurkamal Chatta and his colleagues are conducting a phase I clinical trial of an immunotherapy for men with metastatic prostate cancer that has progressed in spite of standard treatment. “We are targeting an area of need where there are really no other effective therapies.”
Thursday, September 28, 2017 - 2:57pm

“Initially, ovarian cancer, melanoma, and some sarcomas are the three main targets,” says Dr. Koya, “but the clinical trial is open for patients with other cancers who meet the eligibility requirements."

Monday, September 25, 2017 - 10:26am

Collected last week from a patient with late-stage ovarian cancer, these are not ordinary T cells; they have been altered and multiplied in the hope that when they are given back to her, they will launch a devastating attack on her cancer cells. 

Thursday, July 13, 2017 - 2:41pm

Read part I of our series about the new complex immunotherapy trials available here at Roswell Park Cancer Institute.

Monday, June 26, 2017 - 1:47pm

I am the Vice Chair for Translational Research in the Department of Medicine and the Director of Cancer Vaccine and Dendritic Cell Therapies in the Center for Immunotherapy. My goal is to fix cancer-related immune dysfunction and teach our bodies to fight cancer.

Monday, May 1, 2017 - 10:56am

I have been battling cancer successfully for 11 years. Looking back at my first diagnosis — stage 2 breast cancer, at age 42 — I downplay it now, because what happened next was so tragic.

Friday, April 14, 2017 - 10:24am

In December, the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) announced a major collaboration focused on an emerging area of cancer research: neoantigens. These small proteins on the surface of cancer cells arise from mutations often unique to a tumor, making personalized immunotherapies like cancer vaccines a possibility.

Friday, March 24, 2017 - 4:12pm

Rowell Park is exploding in growth, in excitement; we have so many great things to look forward to. One of my visions for the future is that our immunotherapy research and treatments will make us the go-to place for patients that wish to receive innovative cancer therapies.